The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Gori, Stefania ^a   Inno, Alessandro ^a   Fiorio, Elena ^b   Foglietta, Jennifer ^c   Ferro, Antonella ^d   Gulisano, Marcella ^e   Pinotti, Graziella ^f   Gubiotti, Marta ^g   Cavazzini, Maria Giovanna ^h   Turazza, Monica ^a   Duranti, Simona ^a   De Simone, Valeria ⁱ   Iezzi, Laura ^j   Bisagni, Giancarlo ^k   Spazzapan, Simon ^l   Cavanna, Luigi ^m   Saggia, Chiara ⁿ   Bria, Emilio ^b   Cretella, Elisabetta ^o   Vici, Patrizia ^p   Santini, Daniele ^q   Fabi, Alessandra ^p   Garrone, Ornella ^r   Frassoldati, Antonio ^s   Amaducci, Laura ^t   Saracchini, Silvana ^u   Evangelisti, Lucia ^v   Barni, Sandro ^w   Gamucci, Teresa ^x   Mentuccia, Lucia ^x   Laudadio, Lucio ^y   Zoboli, Alessandra ^z   Marchetti, Fabiana ^a   Bogina, Giuseppe ^a   Lunardi, Gianluigi ^a   Boni, Luca ^aa   more..

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e SAN BORTOLO HOSPITAL   (Italy)

^f UNIVERSITY OF INSUBRIA   (Italy)

^g Ospedale Civile di Macerata   (Italy)

^h Unit of Hematology and Oncology AO Carlo Poma   (Italy)

ⁱ IRCCS POLICLINICO SAN DONATO   (Italy)

^j Ospedale Clinicizzato SS Annunziata   (Italy)

^k Medical Oncology Service   (Italy)

^l CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^m GUGLIELMO DA SALICETO HOSPITAL   (Italy)

ⁿ MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^o Medical Oncology Service   (Italy)

^p REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^q UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^r Azienda Ospedaliera   (Italy)

^s UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^t Ospedale per gli Infermi di Faenza   (Italy)

^u S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^v ASL CN1   (Italy)

^w TREVIGLIO HOSPITAL   (Italy)

^x ASL Frosinone   (Italy)

^y Dipto Medicina Interna   (Italy)

^z Ospedale San Sebastiano   (Italy)

^aa CAREGGI UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PHARMACEUTICAL VEHICLES AND ADDITIVES; TUMOR PROTEIN;

ADJUVANT SYSTEMIC THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PROLIFERATION INDEX; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; AGE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIAL; DISEASE MANAGEMENT; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS;

ADJUVANTS, PHARMACEUTIC; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE MANAGEMENT; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRASTUZUMAB; TUMOR BURDEN;

EID: 84945217649     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136731     Document Type: Article

References (30)

1. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer Staging Manual ( ed. 7). Springer-Verlag New York
2. Schmidt F, Hartwagner KA, Spork EB, Groell R (1998) Medical audit after 26,711 breast imaging studies: improved rate of detection of small breast carcinomas (classified as Tis or T1a,b). Cancer 83:2516-2520. PMID: 9874457
3. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. (2007) Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25:4952-4960. PMID: 17971593
4. Slamon DJ1, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. (1989) Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712. PMID: 2470152
5. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, et al. (2009) Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699. doi: 10.1200/JCO.2009.22.0962 PMID: 19884553
6. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706 doi: 10.1200/JCO. 2009.23.2025 PMID: 19884543
7. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, et al. (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9:923-930. PMID: 12631589
8. Petrelli F, Barni S (2012) Role of HER2-neu as a prognostic factor for survival and relapse in pT1abN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Med Oncol 29:2586-2593. doi: 10.1007/s12032-012-0201-4 PMID: 22415399
9. Fehrenbacher L, Capra AM, Quesenberry CP Jr, Fulton R, Shiraz P, Habel LA (2014) Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b nodenegative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol 32:2151-2158. doi: 10.1200/JCO.2013.52.0858 PMID: 24888815
10. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, et al. (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32:2142-2150. doi: 10.1200/JCO.2013.53.1608 PMID: 24888816
11. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684. PMID: 16236738
12. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, et al. (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744-3752. doi: 10.1200/JCO.2014.55.5730 PMID: 25332249
13. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. (2011) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29:4491-4497. doi: 10.1200/JCO.2011.36.7045 PMID: 22042958
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672. PMID: 16236737
15. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244. doi: 10.1016/S1470-2045(11)70033-X PMID: 21354370
16. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283. doi: 10.1056/NEJMoa0910383 PMID: 21991949
17. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354:809-820. PMID: 16495393
18. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27:5685-5692. doi: 10.1200/JCO. 2008.21.4577 PMID: 19884557
19. Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134. doi: 10.1200/JCO.2009.23.0946 PMID: 19917839
20. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134-141. doi: 10. 1056/NEJMoa1406281 PMID: 25564897
21. McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, et al. (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461-5468. doi: 10.1002/cncr.26171 PMID: 21681735
22. Rodrigues MJ, Peron J, Frénel JS, Vano YA, Wassermann J, Debled M, et al. (2013) Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol 24:916-924. doi: 10.1093/annonc/mds536 PMID: 23104720
23. Horio A, Fujita T, Hayashi H, Hattori M, Kondou N, Yamada M, et al. (2012) High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol 17:131-136. doi: 10.1007/s10147-011-0269-4 PMID: 21681642
24. Zhou Q, Yin W, Du Y, Lu J (2014) For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures. PLoS One 9:e83646. doi: 10.1371/journal.pone.0083646 PMID: 24392090
25. Kennedy T, Stewart AK, Bilimoria KY, Patel-Parekh L, Sener SF, Winchester DP (2007) Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients. Ann Surg Oncol 14:2918-2927. PMID: 17638060
26. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, et al. (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504-1513. PMID: 17453008
27. Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32:927-934. doi: 10.1200/JCO.2013.51.1261 PMID: 24516021
28. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28:3422-3428. doi: 10.1200/JCO.2009.26.0463 PMID: 20530280
29. Kolben T, Harbeck N, Wuerstlein R, Schubert-Fritschle G, Bauerfeind I, Schrodi S, et al. (2015) Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b)- Results from the Munich Cancer Registry. Breast 24:24-31. doi: 10.1016/j.breast.2014.10.007 PMID: 25543874
30. Houvenaeghel G, Goncalves A, Classe JM, Garbay JR, Giard S, Charytensky H, et al. (2014) Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. Ann Oncol 25:623-628. doi: 10.1093/annonc/mdt532 PMID: 24399079